Perigon Wealth Management’s United Therapeutics UTHR Stock Holding History

Perigon Wealth Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$322K	Buy	594 +48	+9%	+$27K	0.01%	1074
2026 Q1	$324K	Sell	546 -342	-39%	-$170K	0.01%	990
2025 Q4	$432K	Buy	+888	New	+$414K	0.01%	860
2018 Q2	–	Sell	-105	Closed	-$12K	–	569
2018 Q1	$12K	Hold	105	–	–	﹤0.01%	496
2017 Q4	$16K	Hold	105	–	–	0.01%	443
2017 Q3	$12K	Hold	105	–	–	﹤0.01%	497
2017 Q2	$14K	Hold	105	–	–	﹤0.01%	475
2017 Q1	$14K	Hold	105	–	–	﹤0.01%	497
2016 Q4	$16K	Hold	105	–	–	﹤0.01%	505
2016 Q3	$12K	Buy	105 +50	+91%	+$6.01K	﹤0.01%	464
2016 Q2	$6K	Buy	+55	New	+$6.13K	﹤0.01%	395

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Perigon Wealth Management's UTHR Position: Q2 2026 in Review

Perigon Wealth Management increased its United Therapeutics (UTHR) stake by 8.8% in Q2 2026, buying an estimated $27K and bringing the position to 594 shares worth $322K. The position accounts for 0.01% of the portfolio, ranked #1074.

Perigon Wealth Management first reported a position in UTHR in Q2 2016 and has held it in 11 quarters since. The position peaked at $432K in Q4 2025. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Perigon Wealth Management held 594 shares of United Therapeutics worth $322K as of Q2 2026.
Perigon Wealth Management bought 48 United Therapeutics shares in Q2 2026, an estimated $27K.
United Therapeutics made up 0.01% of Perigon Wealth Management's portfolio in Q2 2026, its #1074 holding.
Perigon Wealth Management first reported a position in United Therapeutics in Q2 2016 and has held it in 11 quarters since.
Perigon Wealth Management's United Therapeutics position peaked at $432K in Q4 2025.
875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Perigon Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.